Business Description
Processa Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US74275C3043
Total Employee Number:
12Description
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The four NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS11T, also referred to as NGC-Iri, is an analog of SN38, and PCS11T, PCS12852, and PCS499.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 65.04 | |||||
Equity-to-Asset | 0.56 | |||||
Debt-to-Equity | 0.01 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 74 | |||||
3-Year EPS without NRI Growth Rate | 74.3 | |||||
3-Year FCF Growth Rate | 68.5 | |||||
3-Year Book Growth Rate | -79 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 66.95 | |||||
9-Day RSI | 56.02 | |||||
14-Day RSI | 50.44 | |||||
3-1 Month Momentum % | -28.52 | |||||
6-1 Month Momentum % | -41.07 | |||||
12-1 Month Momentum % | -65.55 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.98 | |||||
Quick Ratio | 0.98 | |||||
Cash Ratio | 0.85 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -331.6 | |||||
Shareholder Yield % | -226.23 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -299.05 | |||||
ROA % | -214.31 | |||||
ROIC % | -918.34 | |||||
3-Year ROIIC % | 661.88 | |||||
ROC (Joel Greenblatt) % | -77811.83 | |||||
ROCE % | -306.8 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 2.27 | |||||
Price-to-Tangible-Book | 2.27 | |||||
EV-to-EBIT | -0.03 | |||||
EV-to-Forward-EBIT | -0.15 | |||||
EV-to-EBITDA | -0.03 | |||||
EV-to-FCF | -0.04 | |||||
Earnings Yield (Greenblatt) % | -3333.33 | |||||
FCF Yield % | -204.92 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:PCSA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Processa Pharmaceuticals Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -10.596 | ||
| Beta | 2.6629 | ||
| 3-Year Sharpe Ratio | -0.78 | ||
| 3-Year Sortino Ratio | -1.1 | ||
| Volatility % | 134.59 | ||
| 14-Day RSI | 50.44 | ||
| 14-Day ATR ($) | 0.253268 | ||
| 20-Day SMA ($) | 2.044 | ||
| 12-1 Month Momentum % | -65.55 | ||
| 52-Week Range ($) | 1.6701 - 14.2425 | ||
| Shares Outstanding (Mil) | 2.77 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Processa Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Processa Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 118 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 27 days | ||
| General meeting for 2026 | 2026-07-30 13:00 | In 20 days | ||
| First quarter earnings results for 2026 | 2026-05-07 | 2.75 (+3.38%) | ||
| Annual report for 2025 | 2026-03-18 | 3.16 (+2.60%) | ||
| 0.04:1 Stock Split | 2025-12-17 | 3.01 (-3.84%) | ||
| Third quarter earnings results for 2025 | 2025-11-06 | 8.50 (-1.88%) | ||
| Second quarter earnings results for 2025 | 2025-08-07 | 5.69 (-6.11%) | ||
| General meeting for 2025 | 2025-06-30 13:00 | 4.91 (-14.17%) | ||
| First quarter earnings results for 2025 | 2025-05-08 | 6.44 (+3.87%) |
Show
Entries
Processa Pharmaceuticals Inc Frequently Asked Questions
What is Processa Pharmaceuticals Inc(PCSA)'s stock price today?
The current price of PCSA is $2.16. The 52 week high of PCSA is $14.24 and 52 week low is $1.67.
When is next earnings date of Processa Pharmaceuticals Inc(PCSA)?
The next earnings date of Processa Pharmaceuticals Inc(PCSA) is 2026-08-07 Est..
Does Processa Pharmaceuticals Inc(PCSA) pay dividends? If so, how much?
Processa Pharmaceuticals Inc(PCSA) does not pay dividend.
Guru Commentaries on NAS:PCSA
No articles.
Press Release
Articles on Processa Pharmaceuticals Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers